trending Market Intelligence /marketintelligence/en/news-insights/trending/lI1CcuECWmsUC96M7zK1uQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Gilead's Descovy backed by US FDA panel as HIV prevention therapy

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Gilead's Descovy backed by US FDA panel as HIV prevention therapy

A U.S. Food and Drug Administration advisory panel has backed Gilead Sciences Inc.'s Descovy combination therapy for the prevention of HIV infection in men and transgender women, Reuters reported.

Descovy is a combination treatment of emtricitabine and tenofovir alafenamide, which is already FDA-approved for treating chronic HIV.

At an advisory committee meeting Aug. 7, the panel voted 16-2 in support of the drug to be used for pre-exposure prophylaxis, or PrEP, to prevent HIV in men and transgender women who have sex with men. This group forms the largest group in the PrEP market, according to Reuters.

However, the panel voted 10-8 against supporting the expanded use of Descovy for cisgender women, noting that little evidence exists to support the drug's use for PrEP in this population.

The advisory panel's decision is not the final word on Descovy, and the FDA has yet to officially rule on the drug's approval. The agency typically follows the advice of the independent panel of experts.

Gilead expects the expanded label for Descovy to be approved in the fourth quarter of 2019.